TY - CHAP
T1 - Targeting the Bone Marrow Microenvironment
AU - Moschetta, Michele
AU - Kawano, Yawara
AU - Podar, Klaus
N1 - Publisher Copyright:
© Springer International Publishing Switzerland 2016.
PY - 2016
Y1 - 2016
N2 - Unprecedented advances in multiple myeloma (MM) therapy during the last 15 years are predominantly based on our increasing understanding of the pathophysiologic role of the bone marrow (BM) microenvironment. Indeed, new treatment paradigms, which incorporate thalidomide, immunomodulatory drugs (IMiDs), and proteasome inhibitors, target the tumor cell as well as its BM microenvironment. Ongoing translational research aims to understand in more detail how disordered BM-niche functions contribute to MM pathogenesis and to identify additional derived targeting agents. One of the most exciting advances in the field of MM treatment is the emergence of immune therapies including elotuzumab, daratumumab, the immune checkpoint inhibitors, Bispecific T-cell engagers (BiTes), and Chimeric antigen receptor (CAR)-T cells. This chapter will review our knowledge on the pathophysiology of the BM microenvironment and discuss derived novel agents that hold promise to further improve outcome in MM.
AB - Unprecedented advances in multiple myeloma (MM) therapy during the last 15 years are predominantly based on our increasing understanding of the pathophysiologic role of the bone marrow (BM) microenvironment. Indeed, new treatment paradigms, which incorporate thalidomide, immunomodulatory drugs (IMiDs), and proteasome inhibitors, target the tumor cell as well as its BM microenvironment. Ongoing translational research aims to understand in more detail how disordered BM-niche functions contribute to MM pathogenesis and to identify additional derived targeting agents. One of the most exciting advances in the field of MM treatment is the emergence of immune therapies including elotuzumab, daratumumab, the immune checkpoint inhibitors, Bispecific T-cell engagers (BiTes), and Chimeric antigen receptor (CAR)-T cells. This chapter will review our knowledge on the pathophysiology of the BM microenvironment and discuss derived novel agents that hold promise to further improve outcome in MM.
KW - Animals
KW - Bone Marrow/pathology
KW - Humans
KW - Multiple Myeloma/pathology
KW - Tumor Microenvironment
KW - Immune checkpoint inhibition
KW - CAR-T cells
KW - Bone marrow microenvironment
KW - BiTEs
KW - Bone marrow
UR - http://www.scopus.com/inward/record.url?scp=84989855294&partnerID=8YFLogxK
U2 - 10.1007/978-3-319-40320-5_6
DO - 10.1007/978-3-319-40320-5_6
M3 - Chapter in book/report
C2 - 27696259
VL - 169
T3 - Cancer Treatment and Research
SP - 63
EP - 102
BT - Plasma Cell Dyscrasias
ER -